Literature DB >> 21176871

FAP-1 and NF-κB expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis.

Y Nariai1, K Mishima, Y Yoshimura, J Sekine.   

Abstract

This study was designed to investigate the feasibility of using Fas-associated phosphatase-1 (FAP-1), nuclear factor kappa B (NF-κB) and p53 as markers for chemo-radio sensitivity in oral squamous cell carcinoma (OSCC). FAP-1 plays a role as an anti-apoptotic factor through Fas-dependent apoptosis after chemo-radiotherapy. NF-κB and p53 might be involved in modulation of FAP-1 expression. FAP-1, NF-κB and p53 expression were immunohistochemically examined using biopsy specimens in 50 OSCC patients treated with chemotherapy and/or radiotherapy. FAP-1 was expressed in 52%, NF-κB in 52% and p53 in 46% of patients. There was no significant difference in FAP-1, p53 or NF-κB expression according to the clinicopathological features. No correlation was found among FAP-1, p53 or NF-κB expression. FAP-1-positive cases showed a poorer survival rate than FAP-1-negative cases (P = 0.0409) and NF-κB-positive cases showed a poorer survival rate than NF-κB-negative cases (P = 0.0018). Multivariate analysis showed that FAP-1 expression, NF-κB expression, clinical stage and age were significant independent variables for survival (clinical stage: P = 0.0016; age: P = 0.0016; NF-κB: P = 0.0314; FAP-1: P = 0.0366). These results suggest that FAP-1 and NF-κB might play a role as chemo-radioresistant factor during chemo-radiotherapy, and FAP-1 and NF-κB expression in OSCC would be feasible markers for chemo-radio sensitivity and prognosis.
Copyright © 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21176871     DOI: 10.1016/j.ijom.2010.10.020

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  6 in total

1.  5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.

Authors:  Wenming Wang; Jing Wang; Min Li; Jianming Ying; Hongmei Jing
Journal:  Int J Mol Med       Date:  2015-07-01       Impact factor: 4.101

Review 2.  Genetic alterations of protein tyrosine phosphatases in human cancers.

Authors:  S Zhao; D Sedwick; Z Wang
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Applicability of preoperative nuclear morphometry to evaluating risk for cervical lymph node metastasis in oral squamous cell carcinoma.

Authors:  Masaaki Karino; Eiji Nakatani; Katsumi Hideshima; Yoshiki Nariai; Kohji Tsunematsu; Koichiro Ohira; Takahiro Kanno; Izumi Asahina; Tatsuo Kagimura; Joji Sekine
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

4.  Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.

Authors:  Naoki Suenaga; Mimi Kuramitsu; Kanae Komure; Ayumi Kanemaru; Kanako Takano; Kazuya Ozeki; Yuka Nishimura; Ryoji Yoshida; Hideki Nakayama; Satoru Shinriki; Hideyuki Saito; Hirofumi Jono
Journal:  Int J Mol Sci       Date:  2019-10-20       Impact factor: 5.923

5.  The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.

Authors:  Sangeeta K Bisheshar; Emma J De Ruiter; Lot A Devriese; Stefan M Willems
Journal:  Oncoimmunology       Date:  2020-04-23       Impact factor: 8.110

Review 6.  NF-κB Expression and Outcomes in Solid Tumors: A Systematic Review and Meta-Analysis.

Authors:  Dang Wu; Pin Wu; Lufeng Zhao; Lijian Huang; Zhigang Zhang; Shuai Zhao; Jian Huang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.